Abstract
Biliary strictures are considered indeterminate when the initial radiologic evaluation and endoscopic retrograde cholangiopancreatography with brush cytology and/or forceps biopsy do not reveal diagnostic findings. Evaluation of these strictures is challenging and often requires a multidisciplinary approach and multiple procedures. Peroral cholangioscopy allows direct visualization of these lesions and targeted tissue acquisition using miniature biopsy forceps. In the past decade, there have been significant improvements in the field of cholangioscopy. These advances have allowed higher-quality image acquisition, easy setup, operation by a single operator, easy maneuverability, and excellent targeted tissue sampling performance. However, the interpretation of cholangioscopic visual findings remains challenging. In this review, we discuss the role of peroral cholangioscopy in the evaluation of indeterminate biliary strictures.
Endoscopic retrograde cholangiopancreatography (ERCP) with standard brush cytology and/or forceps biopsy was one of the first approaches in the evaluation of obstructive biliary and pancreatic duct diseases. However, ERCP does not provide an intraluminal view of the pancreaticobiliary pathology. Cholangiopancreatoscopy overcomes this limitation by allowing direct visualization of the biliary and pancreatic ducts. The first cholangioscope was described in 1941, and the peroral approach was subsequently introduced in the early 1970s [1,2]. The early cholangioscopy system, known as the mother-daughter system, consisted of a mother duodenoscope and a daughter cholangiopancreatoscope. The limitations of this system were the need for two operators, scope fragility, and poor image quality. Over the past decade, there have been significant improvements in cholangioscopy technology. These include improved image quality, easy setup, need for only one operator, and ability to perform targeted biopsies and therapeutic procedures, such as lithotripsy. One of the main indications for cholangioscopy is the evaluation of biliary strictures when imaging, and ERCP with brush cytology and/or biopsy does not yield a definitive diagnosis. These indeterminate biliary strictures present a diagnostic challenge for endoscopists as both malignant and benign etiologies should be considered. Cholangioscopy offers the advantage of direct visualization of the biliary epithelium to assess malignant features and targeted biopsy results of suspected lesions. This review summarizes the role of peroral cholangioscopy in the evaluation of indeterminate biliary strictures.
Cholangioscopy can be performed perorally or percutaneously. The peroral approach can be performed using an ultraslim endoscope (direct peroral cholangioscopy system [DPCS], GIF-XP; Olympus Co., Tokyo, Japan) or a catheter-based system with a single-operator cholangiopancreatoscope (SOCP, SpyGlass Direct Visualization System; Boston Scientific Endoscopy, Marlboro, MA, USA). Table 1 summarizes the features, advantages, and disadvantages of the different cholangioscopy systems.
In the DPCS, an ultraslim gastroscope is advanced in a monorail fashion over a guidewire or with balloon assistance into the biliary tree. This approach requires sphincterotomy or distal duct dilation for advancement of the cholangioscope through the biliary sphincter. The DPCS allows targeted biopsy of mucosal abnormalities or direct treatment of stone diseases. This system has a high-definition video technology with a superior image quality compared with the SOCP. Additional complementary imaging modalities, such as narrow band imaging (NBI) and probe-based confocal laser endomicroscopy (pCLE), can be used to improve the diagnostic yield further. NBI allows enhanced visualization of superficial mucosal capillary and pit patterns and thicker capillaries of the deeper tissues by restricting light to two waveforms (i.e., 415 and 540 nm). pCLE provides histologic-level images by passing a laser light through a confocal aperture. Owing to the required expertise and high cost, the use of this technique is currently only limited to select centers.
In 2007, the first-generation SOCP was introduced to clinical practice. This device was a single-use fibro-optic-based device (fibro-optic SOCP [FSOCP]) that allowed a single operator to complete the procedure. A new digital version of the SOCP (SpyGlass DS, SPY DS; digital SOCP [DSOCP]) has several advantages compared with the fibro-optic-based device. The new system consists of a sterile, single-use SpyScope access and delivery catheter, SpyGlass digital controller, and SpyBite, which is a biliary biopsy forcep. This system utilizes two light-emitting diodes that improve the image quality and provides a wider endoscopic field of view. Further, there is a dedicated aspiration and irrigation channel, and the tapered tip enables a less traumatic advancement across the papilla and strictures.
Peroral cholangioscopy can be utilized for both diagnostic indications and therapeutic applications. Table 2 summarizes the key clinical indications and contraindications for performing cholangioscopy. The two most common indications for peroral cholangioscopy are management of complex bile duct stones and assessment of indeterminate biliary strictures [3,4].
Biliary strictures are considered indeterminate when the initial radiologic evaluation and ERCP with standard brush cytology and/or forceps biopsy do not yield a definitive diagnosis. These strictures can be benign or malignant and can originate from the intra- or extrahepatic biliary tree, pancreas, liver, gallbladder, ampulla, regional lymph nodes, or invasion from other gastrointestinal malignancies and metastases. Evaluation of these strictures is of paramount importance, as early diagnosis avoids unnecessary surgical procedures and yields optimal patient outcomes. Table 3 summarizes the differential diagnosis for benign and malignant biliary strictures. The leading causes of malignant biliary strictures are cholangiocarcinoma and pancreatic cancer [5].
The diagnosis of malignant biliary strictures can be predicted on the basis of cholangioscopic visual characteristics. However, tissue acquisition is required for the final diagnosis and can be performed via ERCP with standard brush cytology and/or forceps biopsy, endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), and cholangioscopy-guided forceps biopsy. ERCP with standard brush cytology and/or forceps biopsy is often the first diagnostic approach employed. However, this is limited by its low sensitivity and high rates of false-negative results. In a systematic review and meta-analysis (nine studies; 730 patients) on the effectiveness of ERCP for detecting malignant biliary strictures, the pooled sensitivities of brushing cytology and forceps biopsy were 45% and 48.1%, respectively. The combination of the two methods increased the sensitivity only to 59.4% [6]. In patients with biliary strictures due to extrinsic compression (e.g., pancreatic tumors or regional lymph nodes), EUS-FNA has a high diagnostic value and should be considered the standard of care [7]. A recent meta-analysis on the diagnostic yield of EUS-FNA (41 studies; 4,766 patients) reported a pooled sensitivity and specificity of 86.8% and 95.8%, respectively, for diagnosing solid pancreatic masses [8]. The limitations of EUS are challenges in accessing proximal biliary strictures and concerns on seeding malignancy along the FNA tract [9,10].
Table 4 summarizes the biliary epithelial visual findings during cholangioscopy. Seo et al. and Fukuda et al. were the first to illustrate these findings and described malignant strictures as lesions with irregularly dilated and tortuous vessels (tumor vessels), nodularity, papillary characteristics, neovascularization, easy oozing, and irregular surface [11,12]. Conversely, benign strictures have smooth mucosa, borders without neovascularization, and papillo-granular mucosa with no obvious mass [11,12]. The strongest feature suggestive of malignancy is the presence of dilated and tortuous vessels, with a reported positive predictive value of up to 100% [13].
Table 5 summarizes the performance of the DPCS in the diagnosis of malignant biliary strictures. The reported sensitivity and specificity of DPCS visual impression for the diagnosis of malignancy are 83%–92% and 84%–92%, respectively [14-16]. In the first US report on the operating characteristics of the DPCS in 96 patients with indeterminate biliary strictures, the sensitivity and specificity were 85% and 84%, respectively [14]. In a feasibility study on the DPCS with the addition of NBI compared with the use of high-definition white light, Itoi et al. reported an improved visualization of both the surface structures and vessels with the use of NBI [17]. They also reported the detection of four out of 21 lesions on NBI that were not seen with the use of high-definition white light [17].
Table 6 summarizes the data on the diagnostic yield of SOCP visual impression for indeterminate biliary strictures [18-34]. The reported sensitivity, specificity, and accuracy ranged from 78% to 100%, from 77% to 97.6%, and from 80% to 97%, respectively (Table 7) [6,9,14,35-37]. In the report by Chen at al. (226 patients from 15 centers), FSOCP visual impression was found to be more sensitive and specific than ERCP fluoroscopic impression for diagnosing malignant biliary strictures (sensitivity, 78% vs. 51%; specificity, 82% vs. 54%, respectively). This study also found a higher sensitivity for strictures caused by intrinsic lesions than for those caused by extrinsic lesions (84% vs. 61%, respectively) [19]. In a systematic review and meta-analysis on the diagnostic yield of the FSOCP based on visual impression (a total of six studies; 456 patients), the pooled sensitivity and specificity for diagnosing malignant biliary strictures were 84.5% and 82.6%, respectively [38].
The visual diagnostic yield of the second-generation DSOCP (SPY DS) is reported to be higher than that of the first-generation FSOCP. In a multicenter study (two centers; 44 patients), the sensitivity and specificity of DSOCP visual impression for the diagnosis of malignant biliary strictures were 90% and 95.8%, respectively [34]. In another similar study, the sensitivity and specificity of DSOCP visual impression were 95.5% and 94.5%, respectively [26]. Recently, Mizrahi et al. compared the diagnostic yield of visual impression between the FSOCP and DSOCP for malignant biliary strictures (324 patients; FSOCP, 198 and DSOCP, 126) and reported a higher diagnostic yield with the DSOCP than with the FSOCP (78% vs. 37%, respectively, p=0.004) [39].
To date, there is a lack of uniformity as well as a poor inter-observer agreement among experts for interpreting the visual impression of biliary strictures. Moreover, in some instances, such as benign extrinsic compression and irregular biliary mucosal pattern in primary sclerosing cholangitis, visual impression can be misleading and may result in false-positive malignant diagnoses [12,40].
Several studies have evaluated the diagnostic yield of DPCS-guided biopsy for indeterminate biliary strictures (Table 5) [14-17,41]. In the report by Mounzer et al. on the diagnostic yield of DPCS-guided biopsy for malignant biliary strictures (96 patients), the sensitivity and specificity were 43% and 97%, respectively [14]. Table 6 summarizes the performance of SOCP-guided biopsy in diagnosing malignant biliary strictures [18-34]. The reported sensitivity, specificity, and accuracy of this technique were 49% to 100%, 82% to 100% and 55% to 100%, respectively (Table 7) [6,9,14,35-37]. In a multicenter study (140 patients from 15 centers) on the diagnostic yield of FSOCP-guided biopsy, the sensitivity and specificity for diagnosing malignant biliary strictures were 49% and 98%, respectively. This study also reported a higher sensitivity for intrinsic lesions than for extrinsic lesions (66% vs. 8%, respectively). This difference highlights an important limitation of cholangioscopy biopsy forceps, i.e., inability to reach extrinsic lesions for tissue sampling in a significant number of patients [19]. In a systematic review on the diagnostic yield of FSOCP-guided biopsy for malignant biliary strictures, the pooled sensitivity and specificity were 60% and 98%, respectively [38].
The first study on the diagnostic yield of DSOCP-guided biopsy for malignant biliary strictures (two centers; 44 patients) reported a sensitivity and specificity of 85% and 100%, respectively [34]. Another similar study (six centers; 250 procedures) reported a sensitivity and specificity of 57% and 100%, respectively [26].
Limited data suggest that the diagnostic yield of cholangioscopy-guided biopsy may be improved by rapid on-site evaluation using a method of touch imprint cytology, with reported sensitivity and accuracy of 100% and 93.5%, respectively, for diagnosing malignant biliary strictures [35]. However, more studies are needed to illustrate the cost-effectiveness of this approach further.
Table 8 summarizes the available data on overall cholangioscopy-related adverse events (AEs) [14-16,18-27,29-34,42]. The overall AE rate of the SOCP for both diagnostic and therapeutic procedures was between 2% and 30%. The AEs included cholangitis, pancreatitis, hemobilia, bile leak, and rare and serious AEs, such as air embolization and bile duct perforation. Sethi et al. compared the AE rate between 402 patients who underwent ERCP with cholangioscopy and 3,475 patients who underwent ERCP only and reported a higher overall AE rate in the former group of patients (7% vs. 2.9%, respectively; odds ratio [OR], 2.5; 95% confidence interval [CI], 1.56–3.89) [43]. Their subgroup analysis also revealed a higher rate of cholangitis in the former group (1.0% vs. 0.2%, respectively, OR, 4.95; 95% CI, 1.06–19.67), with similar rates of pancreatitis and perforation [43]. In a systematic review including 49 studies on the SOCP and DPCS, the overall and severe AE rates were 7% and 1%, respectively, with cholangitis being the most common AE (4%) [44]. Turowski et al. reported an AE rate of 13.2% in 250 patients who underwent surgery using the DSOCP, with cholangitis being the most common AE (8%) [26]. Prophylactic pre-procedural antibiotics were administered in 40% (102) of the patients, which resulted in a significantly lower rate of cholangitis in comparison with those who did not receive antibiotic prophylaxis (n=148, 60%) (1% vs. 12.8%, p<0.01). Therefore, administration of peri-procedural antibiotics should be recommended in all patients undergoing cholangioscopy [26]. The recent retrospective multicenter study (three centers; 341 patients) by Bernica et al. compared cholangioscopy-related AEs among 209 patients divided into three different age groups (178 patients aged <65 years; 86 patients aged 65-75 years; and 77 patients aged >75 years) [45]. The overall AE rate was 7.3%, with no significant difference among the three age groups (7.30% for the patients aged <65 years, 6.98% for those aged 65–75 years, and 7.79% for those aged >75 years; p<0.17) [45].
Air embolism is a rare but serious AE of the DPCS and has been reported in 0%–2.3% of procedures. The use of water for better visualization and CO2 instead of air for insufflation is recommended to minimize this fatal AE [46].
There are limited data on the economic impact of the use of cholangioscopy compared with other conventional modalities. Recently, Deprez et al. compared the use of ERCP and the SOCP for the diagnosis of malignant biliary strictures and reported that the use of the SOCP reduces the number of needed procedures by 31% and saves approximately 5% of the allocated budget [47]. Further studies are needed to evaluate the cost-effectiveness of the SOCP in other clinical settings.
The evaluation of indeterminate biliary strictures presents a diagnostic challenge, and early precise diagnosis is important for achieving optimal patient outcomes and avoiding unnecessary surgical procedures. Radiologic evaluation is useful to detect and characterize strictures and select the best endoscopic diagnostic technique. In patients with biliary strictures due to extrinsic compression (e.g., pancreatic tumors or regional lymphadenopathy) and those with distal biliary lesions, EUS-FNA should be considered as the first endoscopic procedure. If EUS-FNA reveals no diagnostic findings, ERCP with cholangioscopy should be performed next and possibly during the same session. The new-generation DSOCP has improved the image quality and is safe even in the geriatric population. However, the interpretation of cholangioscopic visual findings remains challenging, and to date, there is a lack of uniformity and a poor inter-observer agreement among experts for the visual interpretation of indeterminate biliary strictures. Although miniature biopsy forceps are essential in the sampling of indeterminate strictures, the yield is suboptimal in certain patients. Studies focusing on the optimization of biopsy techniques and handling of procured specimens are needed.
REFERENCES
1. McIver MA. Instrument for visualizing interior of the common duct at operation. Surgery. 1941; 9:112–114.
2. Vennes JA, Silvis SE. Endoscopic visualization of bile and pancreatic ducts. Gastrointest Endosc. 1972; 18:149–152.
4. Parsi MA, Jang S, Sanaka M, Stevens T, Vargo JJ. Diagnostic and therapeutic cholangiopancreatoscopy: performance of a new digital cholangioscope. Gastrointest Endosc. 2014; 79:936–942.
5. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 2008; 14:6458–6466.
6. Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc. 2015; 81:168–176.
7. Khashab MA, Fockens P, Al-Haddad MA. Utility of EUS in patients with indeterminate biliary strictures and suspected extrahepatic cholangiocarcinoma (with videos). Gastrointest Endosc. 2012; 76:1024–1033.
8. Puli SR, Bechtold ML, Buxbaum JL, Eloubeidi MA. How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: a meta-analysis and systematic review. Pancreas. 2013; 42:20–26.
9. Sadeghi A, Mohamadnejad M, Islami F, et al. Diagnostic yield of EUS-guided FNA for malignant biliary stricture: a systematic review and meta-analysis. Gastrointest Endosc. 2016; 83:290–298. e1.
10. Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford). 2011; 13:356–360.
11. Seo DW, Lee SK, Yoo KS, et al. Cholangioscopic findings in bile duct tumors. Gastrointest Endosc. 2000; 52:630–634.
12. Fukuda Y, Tsuyuguchi T, Sakai Y, Tsuchiya S, Saisyo H. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. Gastrointest Endosc. 2005; 62:374–382.
13. Kim HJ, Kim MH, Lee SK, Yoo KS, Seo DW, Min YI. Tumor vessel: a valuable cholangioscopic clue of malignant biliary stricture. Gastrointest Endosc. 2000; 52:635–638.
14. Mounzer R, Austin GL, Wani S, Brauer BC, Fukami N, Shah RJ. Per-oral video cholangiopancreatoscopy with narrow-band imaging for the evaluation of indeterminate pancreaticobiliary disease. Gastrointest Endosc. 2017; 85:509–517.
15. Meves V, Ell C, Pohl J. Efficacy and safety of direct transnasal cholangioscopy with standard ultraslim endoscopes: results of a large cohort study. Gastrointest Endosc. 2014; 79:88–94.
16. Farnik H, Weigt J, Malfertheiner P, et al. A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography. Endoscopy. 2014; 46:16–21.
17. Itoi T, Sofuni A, Itokawa F, et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc. 2007; 66:730–736.
18. Chen YK, Pleskow DK. SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest Endosc. 2007; 65:832–841.
19. Chen YK, Parsi MA, Binmoeller KF, et al. Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc. 2011; 74:805–814.
20. Laleman W, Verraes K, Van Steenbergen W, et al. Usefulness of the single-operator cholangioscopy system SpyGlass in biliary disease: a single-center prospective cohort study and aggregated review. Surg Endosc. 2017; 31:2223–2232.
21. Ogura T, Imanishi M, Kurisu Y, et al. Prospective evaluation of digital single-operator cholangioscope for diagnostic and therapeutic procedures (with videos). Dig Endosc. 2017; 29:782–789.
22. Imanishi M, Ogura T, Kurisu Y, et al. A feasibility study of digital single-operator cholangioscopy for diagnostic and therapeutic procedure (with videos). Medicine (Baltimore). 2017; 96:e6619.
23. Shah RJ, Raijman I, Brauer B, Gumustop B, Pleskow DK. Performance of a fully disposable, digital, single-operator cholangiopancreatoscope. Endoscopy. 2017; 49:651–658.
24. Pereira P, Vilas-Boas F, Peixoto A, Andrade P, Lopes J, Macedo G. How SpyGlass™ may impact endoscopic retrograde cholangiopancreatography practice and patient management. GE Port J Gastroenterol. 2018; 25:132–137.
25. Lenze F, Bokemeyer A, Gross D, Nowacki T, Bettenworth D, Ullerich H. Safety, diagnostic accuracy and therapeutic efficacy of digital single-operator cholangioscopy. United European Gastroenterol J. 2018; 6:902–909.
26. Turowski F, Hügle U, Dormann A, et al. Diagnostic and therapeutic single-operator cholangiopancreatoscopy with SpyGlassDS™: results of a multicenter retrospective cohort study. Surg Endosc. 2018; 32:3981–3988.
27. Ramchandani M, Reddy DN, Gupta R, et al. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions: a single-center, prospective study. Gastrointest Endosc. 2011; 74:511–519.
28. Hartman DJ, Slivka A, Giusto DA, Krasinskas AM. Tissue yield and diagnostic efficacy of fluoroscopic and cholangioscopic techniques to assess indeterminate biliary strictures. Clin Gastroenterol Hepatol. 2012; 10:1042–1046.
29. Draganov PV, Chauhan S, Wagh MS, et al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc. 2012; 75:347–353.
30. Manta R, Frazzoni M, Conigliaro R, et al. SpyGlass single-operator peroral cholangioscopy in the evaluation of indeterminate biliary lesions: a single-center, prospective, cohort study. Surg Endosc. 2013; 27:1569–1572.
31. Woo YS, Lee JK, Oh SH, et al. Role of SpyGlass peroral cholangioscopy in the evaluation of indeterminate biliary lesions. Dig Dis Sci. 2014; 59:2565–2570.
32. Tieu AH, Kumbhari V, Jakhete N, et al. Diagnostic and therapeutic utility of SpyGlass® peroral cholangioscopy in intraductal biliary disease: single-center, retrospective, cohort study. Dig Endosc. 2015; 27:479–485.
33. Kurihara T, Yasuda I, Isayama H, et al. Diagnostic and therapeutic single-operator cholangiopancreatoscopy in biliopancreatic diseases: prospective multicenter study in Japan. World J Gastroenterol. 2016; 22:1891–1901.
34. Navaneethan U, Hasan MK, Kommaraju K, et al. Digital, single-operator cholangiopancreatoscopy in the diagnosis and management of pancreatobiliary disorders: a multicenter clinical experience (with video). Gastrointest Endosc. 2016; 84:649–655.
35. Varadarajulu S, Bang JY, Hasan MK, Navaneethan U, Hawes R, Hebert-Magee S. Improving the diagnostic yield of single-operator cholangioscopy-guided biopsy of indeterminate biliary strictures: ROSE to the rescue? (with video). Gastrointest Endosc. 2016; 84:681–687.
36. Burnett AS, Calvert TJ, Chokshi RJ. Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology: 10-y review of the literature. J Surg Res. 2013; 184:304–311.
37. Mohamadnejad M, DeWitt JM, Sherman S, et al. Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience. Gastrointest Endosc. 2011; 73:71–78.
38. Navaneethan U, Hasan MK, Lourdusamy V, Njei B, Varadarajulu S, Hawes RH. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc. 2015; 82:608–614. e2.
39. Mizrahi M, Khoury T, Wang Y, et al. “Apple Far from the Tree”: comparative effectiveness of fiberoptic single-operator cholangiopancreatoscopy (FSOCP) and digital SOCP (DSOCP). HPB (Oxford). 2018; 20:285–288.
40. Tischendorf JJ, Krüger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy. 2006; 38:665–669.
41. Moon JH, Ko BM, Choi HJ, et al. Direct peroral cholangioscopy using an ultra-slim upper endoscope for the treatment of retained bile duct stones. Am J Gastroenterol. 2009; 104:2729–2733.
42. Tanaka R, Itoi T, Honjo M, et al. New digital cholangiopancreatoscopy for diagnosis and therapy of pancreaticobiliary diseases (with videos). J Hepatobiliary Pancreat Sci. 2016; 23:220–226.
43. Sethi A, Chen YK, Austin GL, et al. ERCP with cholangiopancreatoscopy may be associated with higher rates of complications than ERCP alone: a single-center experience. Gastrointest Endosc. 2011; 73:251–256.
44. Korrapati P, Ciolino J, Wani S, et al. The efficacy of peroral cholangioscopy for difficult bile duct stones and indeterminate strictures: a systematic review and meta-analysis. Endosc Int Open. 2016; 4:E263–E275.
45. Bernica J, Elhanafi S, Kalakota N, et al. Cholangioscopy is safe and feasible in elderly patients. Clin Gastroenterol Hepatol. 2018; 16:1293–1299. e2.
Table 1.
Table 2.
Table 3.
Table 4.
Table 5.
Study | Study design | Patients (n) | Technical success (%) | Visual sensitivity (%) | Visual specificity (%) | Visual accuracy (%) | Biopsy sensitivity (%) | Biopsy specificity (%) | Biopsy accuracy (%) |
---|---|---|---|---|---|---|---|---|---|
Mounzer et al. (2017) [14]a) | Single-center, prospective | 96 | NR | 85 | 84 | NR | 43 | 97 | NR |
Meves et al. (2014) [15] | Single-center, prospective | 84 | 87 | NR | NR | NR | 89.5 | NR | NR |
Farnik et al. (2014) [16] | Multicenter, retrospective | 89 | 88.5 | NR | NR | NR | NR | NR | NR |
Table 6.
Study | Study design | Cholangioscopy system | Patients (n) | Technical success (%) | Visual sensitivity (%) | Visual specificity (%) | Visual accuracy (%) | Biopsy sensitivity (%) | Biopsy specificity (%) | Biopsy accuracy (%) |
---|---|---|---|---|---|---|---|---|---|---|
Chen et al. (2007) [18] | Multicenter, prospective | FSOCP | 22 | 91 | 100 | 77 | 85 | 71 | 100 | 90 |
Chen et al. (2011) [19] | Multicenter, prospective | FSOCP | 226 | 93 and 86a) | 78 | 82 | 80 | 49b) | 98 | 75 |
Ramchandani et al. (2011) [27] | Single-center, prospective | FSOCP | 36 | 100 | 95 | 79 | 89 | 82 | 82 | 82 |
Hartman et al. (2012) [28] | Single-center, retrospective | FSOCP | 89 | NR | 88 | 86 | 87 | 57 | 100 | 78 |
Draganov et al. (2012) [29] | Single-center, prospective | FSOCP | 44 | 97.7 | NR | NR | NR | 76 | 100 | 84 |
Manta et al. (2013) [30] | Single-center, prospective | FSOCP | 52 | 100 | NR | NR | NR | 88 | 94 | 90 |
Woo et al. (2014) [31] | Single-center, retrospective | FSOCP | 32 | 96 | 100 | 90 | 96 | 64 | 100 | 73 |
Tieu et al. (2015) [32] | Single-center, retrospective | FSOCP | 39 | 92.3 | NR | NR | 97 | NR | NR | 72 |
Kurihara et al. (2016) [33] | Multicenter, prospective | FSOCP | 89 | 95.5 | 94 | 92 | 94 | 65 | 89 | 70 |
Navaneethan et al. (2016) [34] | Multicenter, prospective | DSOCP | 44 | 100 | 90 | 96 | NR | 85 | 100 | NR |
Laleman et al. (2017) [20] | Single-center, prospective | FSOCP | 45 | 88.9 | 83 | 83 | 83 | 85 | 100 | 95 |
Ogura et al. (2017) [21] | Single-center, prospective | DSOCP | 25 | 100 | 83 | 89 | 93 | 80 | 100 | 89 |
Imanishi et al. (2017) [22] | Single-center, retrospective | DSOCP | 20 | 100 | NR | NR | NR | NR | NR | 100 |
Shah et al. (2017) [23] | Multicenter, prospective | DSOCP | 58 | 100 | 97 | 93 | 94 | 86 | 100 | 91 |
Pereira et al. (2018) [24] | Single-center, retrospective | DSOCP | 12 | 100 | NR | NR | 87.5 | NR | NR | 55 |
Lenze et al. (2018) [25] | Single-center, retrospective | DSOCP | 41 | 98.5 | 88.9 | 97.6 | NR | 62.5 | 90 | NR |
Turowski et al. (2018) [26] | Multicenter, retrospective | DSOCP | 99 | NR | 95.5 | 94.5 | NR | 57.7 | 100 | NR |
DSOCP, digital single-operator cholangiopancreatoscope; FSOCP, fibro-optic single-operator cholangiopancreatoscope; NR, not reported.
Table 7.
Diagnostic method | Sensitivity (%) | Specificity (%) | Accuracy (%) |
---|---|---|---|
ERCP with brushing cytology | 23-62.5 | 26-100 | 31-81.3 |
ERCP with standard forceps biopsy | 43-91 | 97-100 | 30-93 |
Combined ERCP with brush cytology and biopsy | 60-70 | 100 | 50 |
ERCP plus FISH | 30-79 | 91-100 | 72-80 |
EUS-FNA | 43-86a) | 97 | |
SOCP visual impression | 78-100 | 78-97.6 | 80-97 |
SOCP SpyBite biopsy | 49-100 | 82-100 | 55-100 |
SpyGlass with ROSE | 100 | 93 | |
DPCS visual impression | 83-92 | 84-92 | |
DPCS biopsy | 43-89.5 | 97 | |
Combined DPCS visual impression plus biopsy | 85 | 84 |
Table 8.
Study | Cholangioscopy system | Sample size (n) | Overall adverse events (%) | Most common adverse event (%) | Severe adverse events (%) |
---|---|---|---|---|---|
Mounzer et al. (2017) [14] | DPCS | 96 | 2 | Bleeding (1) | Perforation (1) - conservative management |
Meves et al. (2014) [15] | DPCS | 84 | 12 | NR | 0 |
Farnik et al. (2014) [16] | DPCS | 89 | 7.7 | Cholangitis (1.5) | 0 |
Bleeding (1.5) | |||||
Chen et al. (2011) [19] | FSOCP | 297 | 7.5 | Cholangitis (3.5) | 0 |
Kurihara et al. (2016) [33] | FSOCP | 89 | 5.4 | Cholangitis (2.7) | 0 |
Laleman et al. (2017) [20] | FSOCP | 84 | 21.4 | Mild pancreatitis (7.1) | 0 |
Ogura et al. (2017) [21] | DSOCP | 55 | 6 | Cholangitis (6) | 0 |
Imanishi et al. (2017) [22] | DSOCP | 28 | 4 | NR | 0 |
Shah et al. (2017) [23] | DSOCP | 108 | 3 | NR | 0 |
Lenze et al. (2018) [25] | DSOCP | 67 | 25.4 | Abdominal pain (23.8) | 16.4b) |
Pereira et al. (2018) [24] | DSOCP | 16 | 38 | NR | 0 |
Turowski et al. (2018) [26] | DSOCP | 250 | 13.2 | Cholangitis, 1% with and 12.8% without antibiotics | Perforation (0.4) - conservative management |
Chen et al. (2007) [18] | FSOCP | 35 | 6 | NR | 0 |
Ramchandani et al. (2011) [27] | FSOCP | 36 | 8.3 | Cholangitis (5.6) | 0 |
Draganov et al. (2012) [29] | FSOCP | 26 | 7.7 | NR | 0 |
Manta et al. (2013) [30] | FSOCP | 52 | 3.8 | NR | 0 |
Woo et al. (2014) [31] | FSOCP | 32 | 9.4 | NR | 0 |
Tieu et al. (2015) [32]c) | FSOCP | 88 | 15.9 | Abdominal pain (11.1) | 1.1 |
Tanaka et al. (2016) [42] | DSOCP | 22 | 7.7 | Cholangitis (3.8) | 0 |
Pancreatitis (3.8) | |||||
Navaneethan et al. (2016) [34] | DSOCP | 105 | 2.9 | Cholangitis (1.9) | 0 |
DPCS, direct peroral cholangiopancreatoscopy system; DSOCP, digital single-operator cholangiopancreatoscope; FSOCP, fibro-optic single-operator cholangiopancreatoscope; NR, not reported.
a) Numbers represent the adverse event rate for both diagnostic and therapeutic procedures and includes procedures with both biliary and pancreatic accesses.